Fig. 8: Heparin-binding EGF-like growth factor (HB-EGF) upregulation in NAGLU-silenced H9C2 cardiomyoblasts. | Cell Death & Disease

Fig. 8: Heparin-binding EGF-like growth factor (HB-EGF) upregulation in NAGLU-silenced H9C2 cardiomyoblasts.

From: EGFR activation triggers cellular hypertrophy and lysosomal disease in NAGLU-depleted cardiomyoblasts, mimicking the hallmarks of mucopolysaccharidosis IIIB

Fig. 8

a HB-EGF protein expression levels in H9C2 sh-CTR and H9C2 sh-NAGLU as measured by western blotting analysis. The amount of HB-EGF as measured by densitometry was normalized with respect to the amount of β-actin. The data reported are the mean ± SD of three independent experiments. *P < 0.05. b HB-EGF protein levels in NAGLU sh-H9C2 transfected with HB-EGF siRNA (siHB-EGF) and with a non-targeting siRNA (siCTR) as measured by western blotting analysis. To monitor equal loading of protein in the gel lanes, the blot was probed using anti-β-actin antibody (lower blot). Densitometric analysis of the bands was performed, and the data obtained are reported on the histogram below. The data reported are the mean ± SD of three independent experiments. *P < 0.05. c Expression levels of mRNAs coding for HB-EGF, ANP, and BNP in H9C2 sh-NAGLU transfected with HB-EGF siRNA (siHB-EGF) and with a non-targeting siRNA (siCTR) as measured by quantitative RT-PCR analysis. The amount of HB-EGF, ANP, and BNP mRNAs were normalized with respect to the amount of 18S ribosomal RNA housekeeping gene. The data reported are the mean ± SD of three independent experiments. *P < 0.05

Back to article page